Valproic acid (Depakene). A new anticonvulsant agent.
Valproic acid, a new anticonvulsant, is most effective in absence seizures (simple and complex), but it has produced improvement in tonicclonic seizures, mixed absence with tonic-clonic seizures, and myoclonic epilepsy. It is useful alone or as an adjunct to other anticonvulsants and may allow the dosage of the latter to be reduced. Some patients who are refractory to other anticonvulsants may respond to valproic acid. Adverse reactions occur in about 20% of patients. Gastrointestinal disturbances and drowsiness (usually noted when valproic acid is given with other anticonvulsants) are the most common reactions; hair loss is observed less frequently. Untoward effects are usually transient and do not require discontinuation of use of the drug.
D000818:Animals; D002648:Child; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004347:Drug Interactions; D004831:Epilepsies, Myoclonic / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D005013:Ethosuximide / Q000627:therapeutic use; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D014635:Valproic Acid / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*
D005013:Ethosuximide; D014635:Valproic Acid